| scholarly article | Q13442814 |
| P50 | author | Paul Perco | Q55949965 |
| P2093 | author name string | Rainer Oberbauer | |
| Gert Mayer | |||
| Andreas Heinzel | |||
| Bernd Mayer | |||
| Arno Lukas | |||
| P2860 | cites work | An automated method for finding molecular complexes in large protein interaction networks | Q21284295 |
| BioGRID: a general repository for interaction datasets | Q24538650 | ||
| The Reactome pathway knowledgebase | Q24567743 | ||
| Data, information, knowledge and principle: back to metabolism in KEGG | Q24568332 | ||
| DrugBank 4.0: shedding new light on drug metabolism | Q24568341 | ||
| The IntAct molecular interaction database in 2012 | Q24621004 | ||
| Perspectives on systems biology applications in diabetic kidney disease | Q26823206 | ||
| Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
| PANTHER: a library of protein families and subfamilies indexed by function | Q29547480 | ||
| Database resources of the National Center for Biotechnology Information | Q29614751 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria | Q30431214 | ||
| Serum protein profiles predict coronary artery disease in symptomatic patients referred for coronary angiography | Q31108335 | ||
| Improved elucidation of biological processes linked to diabetic nephropathy by single probe-based microarray data analysis | Q31171322 | ||
| Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease | Q33399420 | ||
| Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease | Q33591146 | ||
| Bardoxolone methyl and kidney function in CKD with type 2 diabetes | Q34194954 | ||
| Quantifying factors for the success of stratified medicine | Q34228544 | ||
| Investigation of known estimated glomerular filtration rate loci in patients with type 2 diabetes. | Q34376653 | ||
| Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease | Q34383685 | ||
| Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. | Q34411671 | ||
| Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer | Q34563697 | ||
| Drug target pharmacogenomics: an overview | Q34706773 | ||
| Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy | Q34754335 | ||
| Connective tissue growth factor (CTGF) expression modulates response to high glucose | Q34946924 | ||
| Transcriptome analysis of human diabetic kidney disease | Q35180096 | ||
| Systems biology of kidney diseases | Q35619034 | ||
| Urinary proteomics for early diagnosis in diabetic nephropathy | Q36410737 | ||
| HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools | Q37061603 | ||
| Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy | Q37066937 | ||
| The productivity crisis in pharmaceutical R&D. | Q37883027 | ||
| Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review | Q37931336 | ||
| Systems biology: building a useful model from multiple markers and profiles | Q38059187 | ||
| Connective tissue growth factor, matrix regulation, and diabetic kidney disease | Q38063801 | ||
| Transforming growth factor-β and the progression of renal disease | Q38137015 | ||
| Combating oxidative stress in diabetic complications with Nrf2 activators: how much is too much? | Q38190096 | ||
| Implementing precision medicine initiatives in the clinic: a new paradigm in drug development | Q38202843 | ||
| Microalbuminuria: target for renoprotective therapy PRO. | Q38206640 | ||
| Functional molecular units for guiding biomarker panel design | Q38208681 | ||
| Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. | Q38343234 | ||
| Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). | Q44242786 | ||
| A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. | Q44319128 | ||
| Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy | Q44871811 | ||
| Combined angiotensin inhibition for the treatment of diabetic nephropathy | Q46129784 | ||
| Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. | Q46426098 | ||
| Aliskiren combined with losartan in type 2 diabetes and nephropathy | Q46558669 | ||
| Molecular models of the cardiorenal syndrome. | Q46899838 | ||
| Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus. | Q50749591 | ||
| The role of tubulointerstitial inflammation in the progression of chronic renal failure. | Q52601000 | ||
| New therapies for diabetic kidney disease. | Q54636268 | ||
| Preparing for Precision Medicine | Q58045547 | ||
| Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis | Q73267274 | ||
| MCP-1 and RANTES are expressed in renal cortex of rats chronically treated with nitric oxide synthase inhibitor. Involvement in macrophage and monocyte recruitment | Q74628585 | ||
| Evidence-based medicine versus personalized medicine: are they enemies? | Q83517879 | ||
| Molecular pathways and crosstalk characterizing the cardiorenal syndrome | Q83607975 | ||
| P921 | main subject | biomarker | Q864574 |
| pathophysiology | Q1135939 | ||
| P304 | page(s) | 37 | |
| P577 | publication date | 2014-08-22 | |
| P1433 | published in | Frontiers in Cell and Developmental Biology | Q27725488 |
| P1476 | title | From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action | |
| P478 | volume | 2 |
| Q64108710 | A systems pharmacology workflow with experimental validation to assess the potential of anakinra for treatment of focal and segmental glomerulosclerosis |
| Q37706504 | Aberrant methylation patterns in colorectal cancer: a meta-analysis |
| Q38553911 | Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. |
| Q35718777 | Editorial: Multi-omic data integration |
| Q47626310 | Integrated powered density: Screening ultrahigh dimensional covariates with survival outcomes. |
| Q40730543 | Interaction networks for identifying coupled molecular processes in microbial communities. |
| Q47328605 | Microarray analysis reveals gene and microRNA signatures in diabetic kidney disease |
| Q38460161 | Molecular disease presentation in diabetic nephropathy. |
| Q28468441 | Positioning of Tacrolimus for the Treatment of Diabetic Nephropathy Based on Computational Network Analysis |
| Q42346029 | Precision medicine for managing diabetes |
| Q39631863 | Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus |
| Q38612850 | The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease |
| Q38767679 | The nephrologist of tomorrow: towards a kidney-omic future. |
| Q35992948 | Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer |
Search more.